

A guide to Cancer of the Exocrine Pancreas, Ampulla of Vater and Distal Common Bile Duct Histopathology Reporting

Includes the  International Collaboration on Cancer reporting dataset denoted by *



Clinical details		Macroscopic findings cont.			
S1.02	Clinical info. on request form (complete as narrative or use the structured format below)	Text	Anterior pancreatic	Not applicable __mm	
	*Neoadjuvant therapy	See p2	Bile duct	Not applicable __mm	
	*Operative procedure	See p2	Proximal intestinal/gastric	Not applicable __mm	
	Superior mesenteric vein/Portal vein resection	Not performed Performed, <i>specify vascular resection</i>	Distal intestinal	Not applicable __mm	
	Additional specimens	See p2	Other margin/surface	Not applicable Description of margin/surface __mm	
	Local residual cancer postsurgery	Text	G2.01	Evidence of other abnormality or corexisting pathology	Not present Present
	Involvement of adjacent organs	Text	G2.02	Tissue block for research or tissue bank	Not taken Taken
	New primary cancer or recurrence	See p2	G2.03	Photographs	Not taken Taken
	Describe	Text	S2.08	Block identification key	Text
	Relevant patient or family history	Text	G2.04	Other macroscopic comments	Text
G1.01	Copy to doctor	Text	Microscopic findings		
S1.03	Pathology accession number	Text	S3.01	*Histological tumour type	See p2
S1.04	Principal clinician	Text	S3.02	*Histologic tumour grade	See p2
G1.02	Other clinical information	Text	S3.03	*Extent of invasion	See p2
Macroscopic findings			S3.04	Microscopic tumour site	See p2
S2.01	Specimen labelled as	Text	S3.05	Maximum tumour diameter	__mm Note: Record for each tumour identified
S2.02	*Operative procedure	See p2	S3.06	*Lymphatic and venous invasion	See p3
S2.03	*Tumour focality	See p2	S3.07	*Perineural invasion	Not identified Present
	No. of tumours in specimen	Text	S3.08	Response to neoadjuvant therapy	See p3
S2.04	*Tumour site	See p2	S3.09	Margin status	See p3
S2.05	*Tumour dimensions	See p2	S3.10	*Lymph node (LN) status	No nodes submitted of found OR No. can't be assessed OR — Not involved Involved
	*Additional dimensions (largest tumour)	__mm x __mm		No. of LNs examined	— Not involved Involved
	*Dimensions of additional smaller tumour foci	__mm x __mm x __mm		No. of positive LNs	—
	*Method of measurement (in case of neoadjuvant treatment)	Approach 1 Approach 2	S3.11	*Distant metastases	Not identified Present, <i>specify sites(s)</i>
S2.06	Macroscopic tumour description	Text	G3.06	*Coexistent pathology	See p3
	For multiple tumours the description of each focus should be recorded.		G3.07	Additional microscopic comment	Text
	Type of ampullary tumour	See p2	Ancillary test findings		
S2.07	Macroscopic distance of tumour to margins/surfaces		G4.01	*Ancillary studies	Not performed Performed, <i>specify</i>
	Pancreatic transection	Not applicable __mm			
	Superior mesenteric artery	Not applicable __mm			
	Posterior pancreatic	Not applicable __mm			
	Superior mesenteric vein/vascular groove	Not applicable __mm			

Synthesis and overview

S5.01 ***PATHOLOGICAL STAGING** See p3

S5.02 **Year and edition of staging system** Text

G5.01 Diagnostic summary Text

Include: Operative procedure; Tumour location(s); Tumour type; Tumour size; Tumour grade; Tumour stage; Lymph node status; Margin status.

S5.03 **Overarching comment** Text

G5.02 Edition/version of RCPA protocol Text

S1.02 Clinical information

Text
OR
Information not provided

Neoadjuvant therapy

(Select all that apply)

- Not administered
- Administered
 - o Chemotherapy
 - o Radiotherapy
 - o Other, *specify*

S2.03 Operative procedure

Not specified

OR

Select all that apply:

- Whipple pancreatoduodenectomy
- Pylorus-preserving pancreatoduodenectomy
- Distal pancreatectomy
- Total pancreatectomy
- Subtotal pancreatectomy
- Pancreatic resection (tick one of the options above, extended with one or more of the following additionally resected organs/structures)
 - o Vein
 - Superior mesenteric vein
 - Portal vein
 - o Artery(s)
 - Superior mesenteric artery
 - Common hepatic artery
 - Coeliac trunk
- Other, *specify*

Additional specimens

Select all that apply:

- Liver biopsy
- Peritoneal nodules
- Omentum
- Gallbladder
- Spleen
- Other, *specify*

New primary cancer or recurrence

- New primary
- Regional (local) recurrence
- Distant metastases

S3.04 Microscopic tumour site

- Pancreas
 - o Head of pancreas
 - o Neck of pancreas
 - o Body of pancreas
 - o Tail of pancreas
- Uncinate process
- Ampulla of Vater
- Common bile duct (extrapancreatic or intrapancreatic)
- Duodenum
- Other, *specify*

S3.06 Lymphatic and venous invasion

- Not identified
- Present
 - o Lymphatic channel invasion
 - o Venous invasion

S3.07 Response to neoadjuvant therapy

- No neoadjuvant treatment
- Complete response - no viable cancer cells (score 0)
- Near complete response - single cells or rare groups of cancer cells (score 1)
- Partial response - residual cancer with evident tumour regression (score 2)
- Poor or no response - extensive residual cancer with no evident tumour regression (score 3)
- Cannot be assessed, *specify*

S3.09 Margin status

Pancreatic transection margin*

- Not applicable
- Cannot be assessed
- Involved
- Invasive carcinoma
- High grade dysplasia
- Not involved

Distance to closest margin: __mm

Bile duct transection margin*

- Not applicable
- Cannot be assessed
- Involved
- Not involved

Distance to closest margin: __mm

Gastric/proximal duodenal transection margin*

- Not applicable
- Cannot be assessed
- Involved
- Not involved

Distance to closest margin: __mm

Posterior dissection margin*

- Not applicable
- Cannot be assessed
- Involved
- Not involved

Distance to closest margin: __mm

Superior mesenteric artery (SMA) dissection margin*

- Not applicable
- Cannot be assessed
- Involved
- Not involved

Distance to closest margin: __mm

Superior mesenteric vein (SMV) dissection margin*

- Not applicable
- Cannot be assessed
- Involved
- Not involved

Distance to closest margin: __mm

Anterior pancreatic surface*

- Not applicable
- Cannot be assessed
- Involved
- Not involved

Distance to closest margin: __mm

Transection margins of venous resection*

- Not applicable
- Cannot be assessed
- Involved
- Not involved

Distance to closest margin: __mm

Transection margins of arterial resection*

- Not applicable
- Cannot be assessed
- Involved
- Not involved

Distance to closest margin: __mm

Other margin(s)*

- Not applicable
- Cannot be assessed
- Involved
- Not involved

Distance to closest margin: __mm

* If not involved by invasive carcinoma, estimate distance to closest margin.

G3.01 Coexistent pathological abnormalities

Select all that apply:

- Chronic pancreatitis
- Pancreatic intraepithelial neoplasia, *specify highest grade*
- Intraductal papillary mucinous neoplasia, *specify highest grade*
- Neuroendocrine tumour, *specify grade*
- Other, *specify*

Regional lymph node (pN)

- NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Metastasis in one to three regional lymph nodes
N2 Metastasis in four or more regional lymph nodes

Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Eighth Edition (2016) published by Springer Science and Business Media LLC, www.springerlink.com

S5.01 Pathological staging (AJCC 8th edition)##

Suffixes

m - multiple primary tumours; y - post therapy; r - recurrent

Primary Tumour (T)

PANCREAS

- TX Primary tumour cannot be assessed
T0 No evidence of primary tumour
Tis Carcinoma *in situ*. This includes high-grade pancreatic intraepithelial neoplasia (PanIn-3), intraductal papillary mucinous neoplasm with high-grade dysplasia, intraductal tubulopapillary neoplasm with high-grade dysplasia, and mucinous cystic neoplasm with high-grade dysplasia.
T1 Tumour ≤ 2 cm in greatest dimension
T1a Tumour ≤ 0.5 cm in greatest dimension
T1b Tumour > 0.5 cm and < 1 cm in greatest dimension
T1c Tumour 1–2 cm in greatest dimension
T2 Tumour > 2 cm and ≤ 4 cm in greatest dimension
T3 Tumour > 4 cm in greatest dimension
T4 Tumour involves celiac axis, superior mesenteric artery, and/or common hepatic artery, regardless of size

AMPULLA OF VATER

- TX Primary tumour cannot be assessed
T0 No evidence of primary tumour
Tis Carcinoma *in situ*.
T1 Tumour limited to ampulla of Vater or sphincter of Oddi (perisphincteric invasion) and/or into the duodenal submucosa
T1a Tumour limited to ampulla of Vater or sphincter of Oddi
T1b Tumour invades beyond the sphincter of Oddi (perisphincteric invasion) and/or into the duodenal submucosa
T2 Tumour invades into the muscularis propria of the duodenum
T3 Tumour directly invades the pancreas (up to 0.5 cm) or tumour extends more than 0.5 cm into the pancreas, or extends into peripancreatic or periduodenal tissue or duodenal serosa without involvement of the coeliac axis or superior mesenteric artery
T3a Tumour directly invades pancreas (up to 0.5 cm)
T3b Tumour extends more than 0.5 cm into the pancreas, or extends into peripancreatic tissue or periduodenal tissue or duodenal serosa without involvement of the coeliac axis or superior mesenteric artery
T4 Tumour involves the coeliac axis, superior mesenteric artery, and/or common hepatic artery, irrespective of size

DISTAL BILE DUCT

- TX Primary tumour cannot be assessed
T0 No evidence of primary tumour
Tis Carcinoma *in situ*/high grade dysplasia
T1 Tumour invades the bile duct wall with a depth less than 5 mm
T2 Tumour invades the bile duct wall with a depth of 5–12 mm
T3 Tumour invades the bile duct wall with a depth greater than 12 mm
T4 Tumour involves the coeliac axis, superior mesenteric artery, and/or common hepatic artery